ClinicalTrials.gg

Program

HICM-188

A development code. Also written as “HiCM-188 therapy”, “HiCM-188 Cells” and “HiCM-188 Chitosan Patch”.

Its studies are mostly in Heart Failure, led by 2 companies.

Furthest: phase 3, since Mar 16, 20264 company-led studies, 4 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
HELP Therapeutics33 open or runningphase 3since Mar 16, 2026Jan 15, 2024Jun 30, 2027phase 3 · NCT07496372
HELP Therapeutics11 open or runningphase 2since Jun 9, 2026Jun 9, 2026Feb 2028phase 2 · NCT07646210

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2024First study: phase 2 study in Heart FailureNew to HELP TherapeuticsHELP Therapeutics · NCT06340048 · 36 enrolled · China
  2. Mar 10, 2026Phase 2 study in Ischemic Heart FailureHELP Therapeutics · NCT07471698 · 16 planned · China
  3. Mar 16, 2026Phase 3 study in Heart FailurePhase 3 reachedHELP Therapeutics · NCT07496372 · 80 planned · China
  4. Jun 9, 2026HELP Therapeutics's first study: phase 2 study in Advanced Heart FailureNew to HELP TherapeuticsHELP Therapeutics · NCT07646210 · 12 planned · United States

Ahead

  1. Nov 10, 2026Primary completion: phase 2 study in Heart FailureHELP Therapeutics · NCT06340048
  2. Jun 30, 2027Primary completion: phase 3 study in Heart FailureHELP Therapeutics · NCT07496372
  3. Feb 2028Primary completion: phase 2 study in Advanced Heart FailureHELP Therapeutics · NCT07646210
  4. Oct 20, 2028Primary completion: phase 2 study in Ischemic Heart FailureHELP Therapeutics · NCT07471698

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07646210Advanced Heart Failure · United States2Not yet recruitingHELP TherapeuticsFeb 202812
NCT07496372Heart Failure · China3RecruitingHELP TherapeuticsJun 30, 202780
NCT07471698Ischemic Heart Failure · China2Not yet recruitingHELP TherapeuticsOct 20, 202816
NCT06340048Heart Failure · China2Active, not recruitingHELP TherapeuticsNov 10, 202636

How it is read

Names in the registry

  • “HiCM-188 therapy”, 2 entries
  • “HiCM-188 Cells”, 1 entry
  • “HiCM-188 Chitosan Patch”, 1 entry

Codes read as this program: HICM188.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.